In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Curis Inc (NASDAQ: CRIS). The company’s shares opened today at $1.75, close to its 52-week low of $1.57.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 10.6% and a 39.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Curis Inc has an analyst consensus of Moderate Buy, with a price target consensus of $8, implying a 357.1% upside from current levels. In a report issued on August 3, SunTrust Robinson also maintained a Buy rating on the stock with a $8 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.35 and a one-year low of $1.57. Currently, Curis Inc has an average volume of 733.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.
